396 related articles for article (PubMed ID: 24696600)
1. Immunosuppressive therapies for inflammatory bowel disease.
Zenlea T; Peppercorn MA
World J Gastroenterol; 2014 Mar; 20(12):3146-52. PubMed ID: 24696600
[TBL] [Abstract][Full Text] [Related]
2. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
3. Classical and recent advances in the treatment of inflammatory bowel diseases.
Sales-Campos H; Basso PJ; Alves VB; Fonseca MT; Bonfá G; Nardini V; Cardoso CR
Braz J Med Biol Res; 2015 Feb; 48(2):96-107. PubMed ID: 25466162
[TBL] [Abstract][Full Text] [Related]
4. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B
Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
[TBL] [Abstract][Full Text] [Related]
5. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
Danese S; Angelucci E
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
de Mattos BR; Garcia MP; Nogueira JB; Paiatto LN; Albuquerque CG; Souza CL; Fernandes LG; Tamashiro WM; Simioni PU
Mediators Inflamm; 2015; 2015():493012. PubMed ID: 26339135
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
[TBL] [Abstract][Full Text] [Related]
8. [Immunopathogenesis of inflammatory bowel diseases].
Neurath MF; Schürmann G
Chirurg; 2000 Jan; 71(1):30-40. PubMed ID: 10662999
[TBL] [Abstract][Full Text] [Related]
9. Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.
Korelitz BI
World J Gastroenterol; 2013 May; 19(20):2979-84. PubMed ID: 23716977
[TBL] [Abstract][Full Text] [Related]
10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapies in inflammatory bowel disease.
Cohen LB; Nanau RM; Delzor F; Neuman MG
Transl Res; 2014 Jun; 163(6):533-56. PubMed ID: 24467968
[TBL] [Abstract][Full Text] [Related]
12. New strategies in the management of inflammatory bowel disease.
Rutgeerts P; Baert F
Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
[TBL] [Abstract][Full Text] [Related]
13. Drug therapy of inflammatory bowel disease.
Sack DM; Peppercorn MA
Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
[TBL] [Abstract][Full Text] [Related]
15. Treating children with inflammatory bowel disease: Current and new perspectives.
Guariso G; Gasparetto M
World J Gastroenterol; 2017 Aug; 23(30):5469-5485. PubMed ID: 28852307
[TBL] [Abstract][Full Text] [Related]
16. Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy.
Kosoy R; Kim-Schulze S; Rahman A; Friedman JR; Huang R; Peters LA; Amir EA; Perrigoue J; Stojmirovic A; Song WM; Ke H; Ungaro R; Mehandru S; Cho J; Dubinsky M; Curran M; Brodmerkel C; Schadt EE; Sands BE; Colombel JF; Kasarskis A; Argmann CA; Suárez-Fariñas M
Cell Mol Gastroenterol Hepatol; 2021; 12(2):599-632. PubMed ID: 33813036
[TBL] [Abstract][Full Text] [Related]
17. New therapies for inflammatory bowel disease: from the bench to the bedside.
Danese S
Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
[TBL] [Abstract][Full Text] [Related]
18. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality?
van Hogezand RA; Verspaget HW
Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802
[TBL] [Abstract][Full Text] [Related]
19. Advances in inflammatory bowel diseases in children.
Michail S; Ramsy M; Soliman E
Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
[TBL] [Abstract][Full Text] [Related]
20. Impact of medical therapies on inflammatory bowel disease complication rate.
Reenaers C; Belaiche J; Louis E
World J Gastroenterol; 2012 Aug; 18(29):3823-7. PubMed ID: 22876033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
